Cost-Effectiveness of Nivolumab Immunotherapy vs. Paclitaxel or Docetaxel Chemotherapy as Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma in China

This study aimed to evaluate and compare nivolumab's cost-effectiveness with chemotherapy in patients with advanced esophageal squamous cell carcinoma from the Chinese healthcare system perspective. To this end, the researchers utilized a partitioned survival model with three mutually exclusive...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Ying-tao, Liu, Tian-xiu, Chen, Jian, Wang, Chang, Chen, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277084/
https://www.ncbi.nlm.nih.gov/pubmed/35844891
http://dx.doi.org/10.3389/fpubh.2022.923619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277084/
https://www.ncbi.nlm.nih.gov/pubmed/35844891
http://dx.doi.org/10.3389/fpubh.2022.923619

Ejemplares similares